Pharmacological therapy for acute spinal cord injury

R. John Hurlbert; Mark N. Hadley; Beverly C. Walters; Bizhan Aarabi; Sanjay S. Dhall; Daniel E. Gelb; Curtis J. Rozzelle; Timothy C. Ryken; Nicholas Theodore

doi:10.1227/NEU.0b013e31827765c6

Pharmacological therapy for acute spinal cord injury

R. John Hurlbert, Mark N. Hadley, Beverly C. Walters, Bizhan Aarabi, Sanjay S. Dhall, Daniel E. Gelb, Curtis J. Rozzelle, Timothy C. Ryken, Nicholas Theodore

Research output: Contribution to journal › Article › peer-review

173 Scopus citations

Abstract

Despite 4 prospective blinded randomized controlled trials investigating the effect of MP in acute SCI, there exists no Class I medical evidence of any beneficial effect.2,4,8,20 Two prospective Class II trials also failed to demonstrate the therapeutic efficacy of MP in SCI.14,29 In total, over 980 patients have received steroids for SCI and over 280 have participated as control subjects within the protocol of a prospective clinical trial-in which, universally, all primary comparisons to establish efficacy have been negative. A variety of Class III medical evidence has been published supporting the neuroprotective effect ofMPin SCI.

Original language	English (US)
Pages (from-to)	93-105
Number of pages	13
Journal	Neurosurgery
Volume	72
Issue number	SUPPL.2
DOIs	https://doi.org/10.1227/NEU.0b013e31827765c6
State	Published - Mar 2013
Externally published	Yes

Keywords

GM-1 ganglioside
Mehtylprednisolone
NASCIS trials
Pharmacologic therapy
Sygen trials

ASJC Scopus subject areas

Surgery
Clinical Neurology

Access to Document

10.1227/NEU.0b013e31827765c6

Cite this

@article{ebf33519fabb44a78d66f5adb5b6a5ce,

title = "Pharmacological therapy for acute spinal cord injury",

abstract = "Despite 4 prospective blinded randomized controlled trials investigating the effect of MP in acute SCI, there exists no Class I medical evidence of any beneficial effect.2,4,8,20 Two prospective Class II trials also failed to demonstrate the therapeutic efficacy of MP in SCI.14,29 In total, over 980 patients have received steroids for SCI and over 280 have participated as control subjects within the protocol of a prospective clinical trial-in which, universally, all primary comparisons to establish efficacy have been negative. A variety of Class III medical evidence has been published supporting the neuroprotective effect ofMPin SCI.",

keywords = "GM-1 ganglioside, Mehtylprednisolone, NASCIS trials, Pharmacologic therapy, Sygen trials",

author = "Hurlbert, {R. John} and Hadley, {Mark N.} and Walters, {Beverly C.} and Bizhan Aarabi and Dhall, {Sanjay S.} and Gelb, {Daniel E.} and Rozzelle, {Curtis J.} and Ryken, {Timothy C.} and Nicholas Theodore",

year = "2013",

month = mar,

doi = "10.1227/NEU.0b013e31827765c6",

language = "English (US)",

volume = "72",

pages = "93--105",

journal = "Neurosurgery",

issn = "0148-396X",

publisher = "Lippincott Williams and Wilkins",

number = "SUPPL.2",

}

TY - JOUR

T1 - Pharmacological therapy for acute spinal cord injury

AU - Hurlbert, R. John

AU - Hadley, Mark N.

AU - Walters, Beverly C.

AU - Aarabi, Bizhan

AU - Dhall, Sanjay S.

AU - Gelb, Daniel E.

AU - Rozzelle, Curtis J.

AU - Ryken, Timothy C.

AU - Theodore, Nicholas

PY - 2013/3

Y1 - 2013/3

N2 - Despite 4 prospective blinded randomized controlled trials investigating the effect of MP in acute SCI, there exists no Class I medical evidence of any beneficial effect.2,4,8,20 Two prospective Class II trials also failed to demonstrate the therapeutic efficacy of MP in SCI.14,29 In total, over 980 patients have received steroids for SCI and over 280 have participated as control subjects within the protocol of a prospective clinical trial-in which, universally, all primary comparisons to establish efficacy have been negative. A variety of Class III medical evidence has been published supporting the neuroprotective effect ofMPin SCI.

AB - Despite 4 prospective blinded randomized controlled trials investigating the effect of MP in acute SCI, there exists no Class I medical evidence of any beneficial effect.2,4,8,20 Two prospective Class II trials also failed to demonstrate the therapeutic efficacy of MP in SCI.14,29 In total, over 980 patients have received steroids for SCI and over 280 have participated as control subjects within the protocol of a prospective clinical trial-in which, universally, all primary comparisons to establish efficacy have been negative. A variety of Class III medical evidence has been published supporting the neuroprotective effect ofMPin SCI.

KW - GM-1 ganglioside

KW - Mehtylprednisolone

KW - NASCIS trials

KW - Pharmacologic therapy

KW - Sygen trials

UR - http://www.scopus.com/inward/record.url?scp=84923472198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923472198&partnerID=8YFLogxK

U2 - 10.1227/NEU.0b013e31827765c6

DO - 10.1227/NEU.0b013e31827765c6

M3 - Article

C2 - 23417182

AN - SCOPUS:84923472198

SN - 0148-396X

VL - 72

SP - 93

EP - 105

JO - Neurosurgery

JF - Neurosurgery

IS - SUPPL.2

ER -

Pharmacological therapy for acute spinal cord injury

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this